Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 17, 2026

Dollar Drops on Middle East Peace Optimism

View original at nasdaq.com
Dollar Drops on Middle East Peace Optimism The dollar index (DXY00) on Friday fell to a 7-week low and finished down by -0.15%. The dollar came under pressure Friday in hopes that an end to the war in Iran is near, curbing safe-haven demand for the dollar…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The US and Iran are negotiating over a three-page plan to end the war, with one element being that the US would release $20 billion in frozen Iranian assets in return for Iran giving up its stockpile of enriched uranium

    60% confidence
  • Risks to the price outlook are tilted to the upside, especially in the near term, while the medium-term implication will depend on the intensity and duration of the war

    60% confidence
  • The ECB needs to stay vigilant to potential inflation risks from the Iran war, but there isn't much hard evidence of second-round effects, so it's difficult to argue there's an obvious case to raise rates

    60% confidence
  • The oil shock in the US is stronger on the inflation side than on growth, and leaving policy unchanged would still restrain inflation

    60% confidence
  • Given higher uncertainty at the moment, June is a better moment than April to decide whether an ECB interest rate response to the Iran war is necessary

    60% confidence
  • Mary Daly favors keeping Fed policy steady

    60% confidence
  • There are two-sided risks to the economy from the Middle East conflict that make policy responses very difficult

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com